阿立哌唑与奥氮平治疗精神分裂症的疗效及对糖脂代谢的影响

Effect on Aripiprazole and Olanzapine in the treatment of schizophrenia and influence on glucolipid metabolism

目的分析阿立哌唑与奥氮平治疗精神分裂症的疗效及对糖脂代谢的影响。方法选取100例在我院接受治疗的精神分裂症患者,随机分为2组,每组50例,实验组给予口服奥氮平治疗,对照组给予口服阿立哌唑治疗。观察3个月,比较2组治疗效果。结果实验组不良反应发生率明显高于对照组,实验组治疗3个月后空腹血糖、餐后2h血糖均较治疗前显著提高,且均显著高于对照组治疗后的水平,差异有统计学意义(P<0.05)。结论奥氮平对精神分裂症患者的血糖、血脂、体质量有显著影响,而阿立哌唑则无明显影响,在临床上应得到进一步推广和应用。

Objective To compare the therapeutic of Aripiprazole and Olanzapine in the treatment of schizophrenia and its influence on glucolipid metabolism. Methods 100 patients with schizophrenia in our hospital were selected and divided into two groups ,50 cases in each group. The experimental group was given oral Olanzapine ,and the control group was given oral Aripi‐prazole. The therapeutic effects of the two groups were compared after 3‐month observation.Results The incidence of adverse reactions in experimental group was significantly higher than that in control group. After 3 months of treatment ,the fasting and 2 h postprandial plasma glucose in experimental group were significantly increased compared with before treatment and were obviously higher than those in control group after treatment. The differences were all statistically significant （P〈0.05）. Conclusion Olanzapine has a significant impact on blood sugar ,blood lipid and body weight of schizophrenics ,while Aripi‐prazole has no obvious effect. Therefore it is worthy of being widely popularized in clinical application.